A deep-learning serial CT biomarker improves survival prediction in immunotherapy-treated NSCLC and outperforms RECIST. Find ...

Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score ...

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.

Immunotherapy for high grade CNS tumors including adult glioblastoma, anaplastic astrocytoma, pediatric high-grade gliomas, ependymoma and medulloblastoma ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1+, a DNA ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.